Formycon invites to conference call on the results of the first quarter of 2026. The conference call will take place on Thursday, May 28, 2026, at 3:00 PM (CEST) in English: https://t.co/L8JC2BVItr
For information on the 2025 financial results and the outlook for 2026, please refer to our corporate news: https://t.co/qbSJSeQT7v
For full details on the financial results, please refer to the Annual Report on our website: https://t.co/lp7v1gHTgp
๐๐จ๐ง๐๐๐ซ๐๐ง๐๐ ๐๐๐ฅ๐ฅ
๐จ๐ง ๐ญ๐ก๐ ๐๐๐ฌ๐ฎ๐ฅ๐ญ๐ฌ ๐๐จ๐ซ ๐ญ๐ก๐ ๐๐๐๐ ๐ ๐ข๐ฌ๐๐๐ฅ ๐๐๐๐ซ
To follow the conference live, please register via the following link: https://t.co/406YS29DRK
Access the replay at: https://t.co/oFL41dd7vw
The European Biotechnology Science & Industry Guide is more than just a โWho's Whoโ of European biotechnology. It also highlights current developments in innovation, deals and financing. With its biosimilar projects, Formycon is happy to be featured in the current edition.
๐ ๐จ๐ซ๐ฆ๐ฒ๐๐จ๐ง ๐ฌ๐๐๐ฎ๐ซ๐๐ฌ ๐ฅ๐ข๐๐๐ง๐ฌ๐ ๐๐๐ญ๐ ๐๐จ๐ซ ๐ ๐๐๐๐๐ ๐ข๐ง ๐๐ฎ๐ซ๐จ๐ฉ๐ ๐๐ง๐ ๐๐ฎ๐ซ๐ญ๐ก๐๐ซ ๐ญ๐๐ซ๐ซ๐ข๐ญ๐จ๐ซ๐ข๐๐ฌ
Market launches by commercialization partners across Europe to start in May 2026
https://t.co/RB5NLK8Tmt
The FDA has approved Nufymcoยฎ, another interchangeable #ranibizumab#biosimilar in the U.S., underscoring Formyconโs pioneering position in high-quality biosimilar #development: https://t.co/5KmDPzlqje
Formycon starts commercial partnering activities for #FYB206: MS Pharma will commercialize the Keytrudaยฎ biosimilar candidate in the #MENA region: https://t.co/yeFWMXSLma
Formycon sets a new standard: FYB201/Ranivisioยฎis the first ranibizumab biosimilar on the European market in a pre-filled syringe presentation
For more information, please check our press release at:
https://t.co/EHdYasvJR4
Preserving vision โ
Anti-VEGF therapies for severe retinopathies
๐๏ธโ On World Sight Day, we we are turning our attention to retinopathies, in other words: diseases of the retina that can be responsible for severe visual impairment and even blindness: https://t.co/AWCkfc2sUK
Formycon and Klinge expand their European commercialization strategy for the Eyleaยฎ biosimilar FYB203 with Horus Pharma as additional commercialization partner
https://t.co/7iezdpV7W7
Dr. Andreas Seidl, Chief Scientific Officer (CSO) of Formycon AG, is Key Expert Speaker and Chairperson of today's first day of the 15th Biosimilars & Biologics Congress 2025 Europe in London.